Accueil・Liste d'Actions・Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals Inc

Fermé

11.46 -2.22

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

11.46

Max

11.89

Chiffres clés
By Trading Economics
Revenu	-4.3M -18M
BPA	-0.19
Employés	37
EBITDA	-5.3M -17M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+150.85% upside

Dividendes
By Acuity
Prochains Résultats	3 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-126M 999M
Ouverture précédente	13.68
Clôture précédente	11.46

Corvus Pharmaceuticals Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

30 sept. 2026, 23:56 UTC

Correlated Moves

Entegris Inc's shares rose in after-market hours, maintaining stability with little change since Wednesday's close, positioned above its 20-day moving average.

30 sept. 2026, 23:56 UTC

Eastman Chemical Co's shares advanced modestly in after-market trading, recovering from an initial dip and closing above its 20-day moving average.

30 sept. 2026, 23:56 UTC

Rambus Inc is seeing a slight uptick in after-market trading, recovering from earlier declines and remaining well above its 20-day moving average.

30 sept. 2026, 23:55 UTC

RingCentral Inc's shares are modestly higher in after-market trading, remaining above the 20-day moving average despite earlier declines during the session.

30 sept. 2026, 23:55 UTC

Arbor Realty Trust Inc is trading modestly higher in after-market hours, recovering from an initial dip to a cumulative return of 0.51%.

30 sept. 2026, 23:55 UTC

Peloton Interactive Inc. is experiencing a modest decline in after-market trading, nearing its lowest point of the day amid broader market pressures.

30 sept. 2026, 23:55 UTC

Hartford Insurance Group Inc declined in after-market hours, continuing a downward trend from Wednesday's close, amid broader market conditions and below its 20-day moving average.

30 sept. 2026, 23:55 UTC

DHT Holdings Inc has remained roughly flat in after-market hours, fluctuating slightly while staying above its 20-day moving average following recent higher closes.

30 sept. 2026, 23:55 UTC

Ready Capital Corp advanced in after-market trading on Wednesday, despite a recent trend of lower daily closes and being significantly below its 20-day moving average.

30 sept. 2026, 23:55 UTC

Dow Inc. traded modestly higher in after-market hours on Wednesday, recovering from an initial dip but remains 4.85% below its 20-day moving average.

30 sept. 2026, 23:52 UTC

South Korea's S&P Global Manufacturing PMI release on October 1, 2026, is anticipated to reveal cautious insights amid declining industrial production and mixed regional economic signals.

30 sept. 2026, 23:52 UTC

South Korea's October export growth forecasted at 0.617%, down from August's 68.7% amid cautious market sentiment and rising import expectations of 21.5%.

30 sept. 2026, 23:52 UTC

Bank of Japan to release Q3 Tankan Index on September 30, with market expectations set at a stable forecast of 25.0 amid cautious optimism among large manufacturers.

30 sept. 2026, 23:52 UTC

ISM Manufacturing PMI for September 2026 set to release on October 1, with a forecast of 55.0 indicating continued sector expansion amid mixed but optimistic U.S. economic sentiment.

30 sept. 2026, 23:52 UTC

Market Awaits ISM Manufacturing Employment Data Release Amid Mixed Economic Signals and Optimism from Other Sectors.

30 sept. 2026, 23:52 UTC

Market Awaits BoJ Summary of Opinions on Monetary Policy Amid Inflation Concerns, Scheduled for September 30, 2026.

30 sept. 2026, 23:52 UTC

Japan's Current Account Release on October 7, 2026, Expected to Influence Investor Sentiment Amidst Macroeconomic Volatility.

30 sept. 2026, 23:51 UTC

Bank of America Corp is moving higher in after-market trading, supported by a broader market rally and stronger-than-expected economic data, including GDP and job growth.

30 sept. 2026, 23:51 UTC

Applied Materials Inc is moving higher in after-market trading, reflecting positive macroeconomic indicators, including an upward revision of U.S. GDP growth for Q2 to 2.2%.

30 sept. 2026, 23:51 UTC

CrowdStrike Holdings Inc is trading modestly lower in after-market hours, following a notable decline from early highs earlier in the session.

30 sept. 2026, 23:51 UTC

ICU Medical Inc is trading higher in after-market hours, supported by positive economic indicators, including a revised U.S. GDP growth rate of 2.2% for Q2.

30 sept. 2026, 23:51 UTC

Social Media

McCormick & Company shares are advancing in after-market trading ahead of earnings, reflecting broader market gains driven by strong economic data.

30 sept. 2026, 23:51 UTC

UWM Holdings Corp is higher in after-market trading, reflecting positive macroeconomic indicators, including an upward revision of Q2 U.S. GDP growth to 2.2%.

30 sept. 2026, 23:51 UTC

Camden Property Trust advanced modestly in after-market trading, recovering from an early low to a late afternoon high amid ongoing volatility.

30 sept. 2026, 23:50 UTC

Healthcare Services Group Inc is trading higher in after-market hours, supported by positive economic indicators and gains across the broader market.

30 sept. 2026, 23:50 UTC

Tilray Brands Inc is trading modestly lower in after-market hours, continuing a trend of declines following three consecutive lower daily finishes.

30 sept. 2026, 23:50 UTC

Penumbra Inc is lower in after-market trading, recovering slightly from earlier losses but remaining near the lower end of its one-month range.

30 sept. 2026, 23:50 UTC

Williams-Sonoma Inc is trading modestly higher in after-market hours, supported by a significant upward movement in the broader market.

30 sept. 2026, 23:50 UTC

Crown Castle Inc is experiencing a higher price movement in after-market trading, reflecting an upward trend in the broader market despite remaining below its 20-day moving average.

30 sept. 2026, 23:50 UTC

Booz Allen Hamilton Holding Corp is rising in after-market trading, supported by stronger-than-expected U.S. GDP growth and private sector job growth in September.

Comparaison

Variation de prix

Corvus Pharmaceuticals Inc prévision

Objectif de Prix

By TipRanks

150.85% hausse

Prévisions sur 12 Mois

Moyen 29.5 USD 150.85%

Haut 33 USD

Bas 27 USD

Basé sur 4 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

4 ratings

Achat

Maintien

Vente

Basé sur 4 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Corvus Pharmaceuticals Inc

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.